Ami Organics - Fast Moving Intermediate Towards Becoming A Midcap Play: KRChoksey Initiates Coverage
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
KRChoksey Research Report
Ami Organics Ltd. has established itself as a trusted and major manufacturer of pharma intermediates and specialty chemicals through its strong capabilities. It is well placed to complement its long-term growth strategy with the support of experienced team, extensive geographical presence and higher entry barriers in the industry.
We believe pharma active pharma ingredient sector has good traction and thus, Ami Organics is set for newer growth opportunities on account of launch and commercialisation of import substitute products, cost efficiencies due to better utilisation levels and enhancement of its product offerings.
Ami Organics made a solid debut in September 2021 at Rs 910, listing at a premium of 49% to the issue price.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.